|
Characteristic, n (%)
|
pCR
|
non-pCR
|
P
|
|---|
|
pT0N0
|
pT0N1-3
|
pT1-4N0
|
pT1-4N1-3
|
|---|
|
n=25
|
n=10
|
n=40
|
n=40
|
|---|
|
Median age (range)
|
63 (44–77)
|
65 (53–75)
|
66 (43–74)
|
63 (41–75)
|
0.2402
|
|
Gender
| | | | |
0.7178
|
|
Female
|
5 (20.0)
|
1 (10.0)
|
8 (20.0)
|
5 (12.5)
| |
|
Male
|
20 (80.0)
|
9 (90.0)
|
32 (80.0)
|
35 (87.5)
| |
|
Tumor location
| | | | |
0.8228
|
|
Upper
|
5 (20.0)
|
2 (20.0)
|
8 (20.0)
|
9 (22.5)
| |
|
Middle
|
9 (36.0)
|
4 (40.0)
|
18 (45.0)
|
21 (52.5)
| |
|
Lower
|
11 (44.0)
|
4 (40.0)
|
14 (35.0)
|
10 (25.0)
| |
|
Tumor differentiation
| | | | |
0.5425
|
|
Not poorly
|
20 (80.0)
|
8 (80.0)
|
36 (90.0)
|
36 (90.0)
| |
|
Poorly
|
5 (20.0)
|
2 (20.0)
|
4 (10.0)
|
4 (10.0)
| |
|
Depth of invasion (cT)
| | | | |
0.0567
|
|
T1-2
|
5 (20.0)
|
3 (30.0)
|
2 (5.0)
|
3 (7.5)
| |
|
T3-4
|
20 (80.0)
|
7 (70.0)
|
38 (95.0)
|
37 (92.5)
| |
|
Lymph node metastasis (cN)
| | | | |
0.5858
|
|
N1
|
18 (72.0)
|
8 (80.0)
|
26 (65.0)
|
24 (60.0)
| |
|
N2-3
|
7 (28.0)
|
2 (20.0)
|
14 (35.0)
|
16 (40.0)
| |
|
Distant metastasis (cM)
| | | | |
0.2138
|
|
M0
|
19 (76.0)
|
10 (100)
|
36 (90.0)
|
35 (87.5)
| |
|
M1 (lymph node)
|
6 (24.0)
|
0 (0)
|
4 (10.0)
|
5 (12.5)
| |
|
Clinical stage(cStage)
| | | | |
0.1051
|
|
I
|
1 (4.0)
|
1 (10.0)
|
2 (5.0)
|
0 (0)
| |
|
II
|
3 (12.0)
|
2 (20.0)
|
0 (0)
|
3 (7.5)
| |
|
III
|
14 (56.0)
|
6 (60.0)
|
34 (85.0)
|
31 (77.5)
| |
|
IVA
|
1 (4.0)
|
1 (10.0)
|
0 (0)
|
1 (2.5)
| |
|
IVB
|
6 (24.0)
|
0 (0)
|
4 (10.0)
|
5 (12.5)
| |
|
Recurrence
| | | | |
0.0456a
|
|
Presence
|
5 (20.0)
|
4 (40.0)
|
15 (37.5)
|
22 (55.0)
| |
|
Absence
|
20 (80.0)
|
6 (60.0)
|
25 (62.5)
|
18 (45.0)
| |
|
Prognosis
| | | | |
0.3115
|
|
Alive
|
22 (88.0)
|
6 (60.0)
|
27 (67.5)
|
24 (60.0)
| |
|
Dead with ESCC
|
2 (8.0)
|
3 (30.0)
|
10 (25.0)
|
14 (35.0)
| |
|
Dead with other diseases
|
1 (4.0)
|
1 (10.0)
|
3 (7.5)
|
2 (5.0)
| |
- pCR pathological complete response, ESCC esophageal squamous cell carcinoma
- *Statistically significant
